



Alnylam to Webcast Presentations at Upcoming February Investor Conferences

February 5, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 5, 2018-- [Alnylam Pharmaceuticals, Inc.](http://www.alnylam.com) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:

- 20th Annual BIO CEO & Investor Conference on Monday, February 12, 2018 at 10:45 am ET at the Marriott Marquis in New York City
- Leerink Partners 7th Annual Global Healthcare Conference on Thursday, February 15, 2018 at 11:00 am ET at the Lotte New York Palace Hotel in New York City

A live audio webcast of each presentation will be available on the Investors section of the Company's website, www.alnylam.com. A replay will be available on the Alnylam website within 48 hours after each event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including four product candidates that are in late-stage development. Looking forward, Alnylam will continue to execute on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 700 people in the U.S. and Europe and is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at [@Alnylam](https://twitter.com/Alnylam) or on [LinkedIn](https://www.linkedin.com/company/alnylam).

View source version on businesswire.com: <http://www.businesswire.com/news/home/20180205005078/en/>

Source: Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

Investors and Media

Christine Regan Lindenboom, 617-682-4340

or

Investors

Josh Brodsky, 617-551-8276